Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors. The company's lead product candidate is nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1, which is in Phase 2 clinical trial. This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.

Skye Bioscience, Inc.

Skye Bioscience ( ($SKYE) ) has issued an announcement. On September 8, 2026, Skye Bioscience terminated its Master Services Agreement with Lohman ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	SKYE	$1.67	-1.76%	43.51K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	SKYE	$1.67	-1.8%	43.51K
3
4
5
6

SKYE

Get Skye Bioscience, Inc. Data in Excel

Get Skye Bioscience, Inc. Data in Excel